Startups
iOrganBio
iOrganBio, Inc. develops AI-guided manufacturing technology for human cells and organoids used in disease modeling, drug discovery and cell-therapy development. Its CellForge platform combines predicted cell states, biological measurements and automated three-dimensional incubation to control stem-cell differentiation. Genomic, transcriptomic and proteomic feedback informs changes in culture conditions as cells develop toward a partner’s specified biological profile. The resulting cells are delivered with process and endpoint data for comparison against the requested target. CellAtlas supplies digital reference profiles of adult human cells and tissues, helping partners define target cell properties and benchmark laboratory-produced material. The company is developing reproducible, scalable alternatives to manually optimized cell-production methods, including human-relevant models for pancreatic and neurological applications. Its scientific advisers include specialists in human neuronal function and neurodegenerative disease models. Founded in 2024 by Daniel Delubac, Shuibing Chen and Xiling Shen, the company builds on stem-cell differentiation research originating at Weill Cornell Medicine. Its current website lists a Morrisville, North Carolina address; earlier releases describe its Chapel Hill BioLabs location.
Founded 2024